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Background  T-cell receptor (TCR) plays an important role in the development of autoimmune diseases. 
Recently, it was reported that immunization of animals with TCR peptide derived from the pathogenic cells could 
prevent autoimmune diseases. The aim of this study was to investigate whether vaccination with a synthetic 
peptide from the hypervariable region of TCR Vβ 8.3, an experimental autoimmune uveoretinitis 
(EAU)-associated gene, was able to prevent the disease. 
Methods  EAU was induced in Lewis rats by immunization with IRBP R16 peptide emulsified in complete 
Freund's adjuvant (CFA). The clinical and histological appearances were scored. Delayed type hypersensitivity 
(DTH) and lymphocyte proliferation were detected. Cytokine levels of aqueous humour, supernatants of cells 
from spleen and draining lymph nodes were measured by enzyme linked immunosorbent assay (ELISA). Gene 
expression of TCR Vβ 8.3 on CD4+ T cells was examined by real time quantitative polymerase chain reaction 
(PCR). 
Results After vaccination, the intraocular inflammation was significantly mitigated, antigen specific DTH and 
lymphocyte proliferation responses were suppressed, interleukin (IL)-2 in aqueous humour, interferon (IFN)-( 
and IL-2 produced by the spleen and draining lymph node cells were significantly decreased, whereas the 
production of IL-4 and IL-10 were increased. The response of draining lymph node cells to TCR Vβ 8.3 peptide 
was enhanced after vaccination. Inoculation with CFA alone did not affect the severity of EAU and the above 
parameters. The suppression of EAU was much stronger in the group of four fold inoculations than the group of 
two fold inoculations. The expression of TCR Vβ 8.3 gene was significantly reduced in the group of fourfold 
inoculations. 
Conclusion  Vaccination with the synthetic TCR Vβ 8.3 peptide could remarkably inhibit the development of 
EAU. 
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xperimental autoimmune uveoretinitis (EAU) is 
an organ specific, intraocular inflammatory 
disease induced in susceptible species by 
immunization with retinal specific antigens such as 
interphotoreceptor retinoid binding protein (IRBP)1,2 
or its immunodominant epitopes,3 and has been 
considered as a model for human autoimmune 
uveitis. Studies on human uveitis and its animal 
counterpart have revealed that autoreactive CD4+ T 
lymphocytes are primarily responsible for the 
development of this disease.4 Therefore, a desirable 
therapy may involve selective inactivation or 
elimination of these pathogenic T cells.  
 
Uveitis is one of the leading causes of blindness in 
the world. The prevention of uveitis and other autoimmune 
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diseases has been intensively studied during the 
past decades. Of special interest are the promising 
results in the study of regulating antigen specific 
responses in experimental allergic encephalo- 
myelitis (EAE), an organ specific autoimmune animal 
model for multiple sclerosis. It was reported that 
immunization of Lewis rats with synthetic peptides 
derived from T-cell receptor (TCR) of encep 
halitogenic T cell clones could prevent the develop 
ment of EAE.5,6 The underlying mechanisms may 
include the induction of regulatory T cells and 
modulation of Th1/Th2 balance.7 Yet, it is not clear 
whether EAU, like EAE,8 can be prevented by 
disease associated TCR peptide vaccinations. 
Egwuagu and coworkers9 examined the expression 
of genes coding for the 20 variable regions of TCR 
Vβ families in Lewis rats and found that TCR Vβ 8.3 
was most strongly associated with the pathogenic T 
cell subline.  Therefore, we investigated the effect 
of vaccination with EAU specific TCR Vβ 8.3 peptide 
on uveoretinitis in Lewis rats. We also examined the 
expression of TCR Vβ 8.3 gene in the vaccinated rats 
to determine its contribution to the effect of 
vaccination. Our results supported the validity of 
TCR Vβ 8.3 peptide as a vaccine in the prevention of 
EAU with underlying mechanisms similar to those 
suggested in the EAE model.  The additional 
mechanism we propose is the suppression of the 
EAU-associated TCR Vβ 8.3 gene expression after 
multiple vaccinations.  
 
METHODS 
 
Animals  
Eight to ten weeks old, inbred female Lewis rats, 
weighing 150 g to 180 g, were used in this study.  
These rats were treated according to institutional 
and federal guidelines. All animal experimental 
procedures adhered to the Association for Research 
in Vision and Ophthalmology (ARVO) Statement for 
the use of animals in ophthalmic and vision 
research. 
 
Peptides 
The TCR Vβ 8.339-59 (DMGHGLRLIHYSY- 
GSGSFENG), and a uveitogenic peptide IRBP R16 
(ADGSSWEGVGVVPDV) were synthesized using 
Fmoc amino acid standard solid phase techniques 
(CS Inc, USA) according to the manufacturer's 
instruction.  
Vaccine and vaccination  
EAU was induced by injection of 30 µg IRBP R16 
peptide emulsified in complete Freund's adjuvant 
(CFA) containing 2.5 mg/ml of Mycobacterium 
tuberculosis H37Ra, into the left hind footpads of the 
Lewis rats. The peptide vaccine was prepared by 
emulsification of 100 µg Vβ 8.3 peptide in CFA 
containing 1000 µg Mycobacterium tuberculosis 
H37Ra in a volume of 0.1 ml. The vaccine was 
injected into the right footpads of the Lewis rats.  
The experimental rats were divided into 5 groups: 
the normal group (6 rats) receiving no treatments; 
noninoculated group (12 rats) only receiving IRBP 
R16 peptide emulsified in CFA; CFA inoculated 
group (12 rats) receiving injections of an emulsion 
containing phosphate buffered saline (PBS), bacteria 
and CFA for 4 times (on 30, 20, 10 and 0 days before 
R16 peptide immunization); two-fold inoculated 
group (12 rats) receiving injections of peptide 
vaccine on 20 and 0 days before immunization with 
R16 peptide in CFA; and fourfold inoculated group 
(12 rats) receiving the peptide vaccine on 30, 20, 10 
and 0 days before immunization with R16 peptide in 
CFA. Six rats in the last 4 groups were followed up 
for 30 days, whereas the other six rats in these 
groups were sacrificed on day 14 for further studies 
as described below.  
 
Clinical and histological assessment of EAU 
All the rats were monitored daily. Clinical signs were 
scored by slit lamp biomicroscope as follows: 0, 
normal; 1, minimal signs of inflammation with 
occasional cells in the anterior chamber; 2, presence 
of mild exudate in the anterior chamber; 3, moderate 
exudate in the anterior or posterior chamber 
(posterior chamber hypopyon); 4, large exudate 
within the anterior chamber, or massive posterior 
chamber hypopyon; 5, gross orbital oedema and 
exophthalmos in addition to the manifestation listed 
in 4.10 
 
On day 14 after IRBP R 16 peptide immunization, 6 
rats chosen randomly from each group were 
sacrificed and the eyes of each rat were enucleated 
and fixed in 10% formaldehyde. Sections of 5 µm in 
thickness were stained with haematoxylin eosin and 
examined under a light microscope. Histological 
grading was as follows: 0, no inflammatory cell 
infiltration and no destruction of the retina; 1, minimal 
cell infiltration in the retina and choroid but no 
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destruction; 2, partial and mild destruction of the 
outer retina; 3, moderate destruction of the outer 
retina; 4, extensive and severe destruction of the 
outer retina and partial destruction of the inner retina; 
5, complete destruction of the entire retina.11 
 
Assay for delayed type hypersensitivity 
Delayed type hypersensitivity (DTH) response to 
IRBP R16 peptide was determined by measuring the 
thickness of swelling ears.  On day 15 after IRBP 
R16 immunization, 20 µg of R16 peptide in 20 µl 
PBS was injected into the right pinna of each rat.  
PBS was injected into the left pinna as a control.  
Ear thickness was measured with a micrometer 24 
hours after R16 peptide challenge. DTH dependent 
ear swelling was calculated according to the 
following formula:  
 
Specific cell swelling (10-3mm)= 
24 h measurement of right ear－0h measurement of left ear 
24 h measurement of left ear－0h measurement of left ear 
 
Lymphocyte proliferation assay 
The draining lymph nodes at the inguinal areas of 
the rats were collected, minced and passed through 
a wire mesh to obtain a single cell suspension. The 
lymphocyte proliferation assay (LPA) was performed 
in a 96-well plate in triplicate with RPMI 1640 
medium (Gibco, NY, USA) containing streptomycin 
(100 µg/ml), penicillin (100 U/ml), 2 mmol/L 
L-glutamine, 5×10-5 mol/L 2-mercaptoethanol, 0.1 
mmol/L nonessential amino acids, 1 mmol/L sodium 
pyruvate, and 1% syngeneic rat serum. The cells 
were seeded at a density of 2×105 cells per well and 
incubated with the medium alone, stimulated with 
IRBP R 16 or Vβ8.3 peptide (10 µg/ml) at 37˚C in an 
atmosphere of 5% CO2 for 72 hours.  The culture 
wells were pulsed with 37 kBq of 3H-thymidine for 
the last 16 hours and harvested on glass fibre filters.  
The thymidine uptake was assessed by liquid 
scintillation on a beta counter (Packard, USA). 
 
Cytokine assays 
Approximately 20 µl of aqueous humour was 
obtained from both eyes of each rat by paracentesis 
before it was sacrificed. Cells from the spleens and 
draining lymph nodes were incubated in 24-well 
tissue culture plates (2×106 cells/well) with 10 µg/ml 
of R16 in 2 ml of serum free medium as described 
above. The supernatants collected 48 hours after the 
incubation were assessed for IFN-(, IL-2, IL-4 and 
IL-10 and the aqueous humour was assessed for 
IL-2 by a specific sandwich ELISA kit (R&D Systems 
Inc, USA), according to the manufacturer's 
procedure.  
 
Detection of TCR Vβ 8.3 expression by real time 
quantitative PCR 
CD4+ T cells of the spleens were isolated by means 
of magnetic beads using two kinds of antibodies, 
mouse antirat CD4 monoclonal antibody and 
antimouse IgG antibody, conjugated to the magnetic 
beads (Dynal, Norway). The quantitative 
assessment of mRNA levels was performed using 
PE Prism 7000 sequence detection system 
(Perkin-Elmer Applied Biosystems, USA). The 
standard sample was serially diluted to perform real 
time quantitative PCR. The correlation between Ct 
values and copy numbers is linear, with a correlation 
coefficient of 0.999. The final reaction was 
performed in 10 µl 5×quantitative PCR buffer, 2 µl 
(25 µmol/L) primers, 1 µl dNTPs (10 mmol/L), 1 µl 
fluorescent probe (20 µmol/L), 2 µl Taq polymerase 
(2 U/µl), 5 µl cDNA, in a total volume of 50 µl. An 
initial step was 93˚C for 2 minutes. Cycling 
conditions were: 40 cycles of melting at 93˚C for 1 
minute and annealing extension at 55˚C for 1 minute. 
Upstream primer (5'-GGCATGGTCTGAGGCTGA- 
TC-3'), downstream primer (5'-ACCCCTCAGGG- 
ATATCTCCATT-3'), and probe sequence (5'-ATTAC- 
TCATATGGTTCTGGC-3') were used for the 
detection of TCR Vβ 8.3 expression. 
 
Statistical analysis 
Means and standard deviations were calculated for 
the clinical and laboratory measurements.  
Statistical analyses were performed by one way 
ANOVA or Student's t test. EAU scores were 
analyzed by the Snedecor and Cochran's test for 
linear trends in proportions. Probability valuesless 
than 0.05 were considered statistically significant. 
 
RESULTS 
 
Inhibition of IRBP R16 -induced EAU by the TCR 
Vβ 8.3 peptide vaccine  
After IRBP R16 peptide challenge, the clinical scores 
of EAU were evaluated by slit lamp biomicroscope 
examination (Figs. 1 and 2). A severe uveitis, as 
evidenced by ciliary congestion, meiosis, inflammatory 
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cells and exudate in the anterior chamber, was 
observed in the noninoculated rats and CFA 
inoculated rats. In a marked contrast, no clinical 
intraocular inflammation was found in 3 rats of the 
fourfold inoculated group, and a mild inflammation 
was observed in the other 3 rats of this group. A 
moderate inflammation was noted in all of the rats in 
the twofold inoculated group. However, a shorter 
duration and delayed onset of EAU was observed in 
the two vaccination groups as compared with the 
CFA inoculated group as well as the noninoculated 
group (Fig. 2). The fourfold inoculation appeared to 
be more effective than the twofold inoculation. As 
controls, the severity and course of EAU in the CFA 
inoculated rats were not significantly different from 
those in the noninoculated rats.  
 
 
 
Fig. 2. Kinetics of EAU in different groups. Mean clinical 
scores are shown for each group. Non-I: noninoculated 
group; CFA-I: CFA inoculated group; Two-I: twofold 
inoculated group; Four-I: fourfold inoculated group. 
 
A histological analysis was performed on day 14 
after R16 immunization. Consistent with the clinical 
evaluation, severe retinal destruction associated with 
infiltration of numerous inflammatory cells was 
observed in the sections from both the noninoculated 
group and the CFA inoculated group (Figs. 3A, 3B 
and 4). Twelve eyes from the twofold inoculated 
group exhibited mild to moderate inflammation (Figs. 
3c and 4). In the fourfold inoculated group, six eyes 
from the rats with no clinical signs of uveitis did not 
show obvious evidence of intraocular inflammation, 
whereas the other six eyes from the rats with clinical 
scores of 1 to 2 only showed scattered inflammatory 
cells (Figs. 3D and 4).  
  
Suppression of systemic responses after  
TCR Vβ 8.3 peptide vaccination 
In addition to ocular inflammation, immunization with 
IRBP has been shown to induce concurrently 
systemic Th1 mediated responses. To evaluate the 
impact of TCR Vβ 8.3 peptide vaccination on the 
immune system, we measured DTH in vivo and 
lymphocyte proliferation in vitro. DTH response is 
typically manifested by the swelling of ear pinnae, 
which was readily seen in the noninoculated and the 
CFA inoculated groups. In contrast, DTH responses 
to the IRBP R16 peptide were significantly 
suppressed in the vaccinated groups, especially in 
the fourfold inoculated group (Fig. 5). 
 
The lymph node cells (LNCs) from noninoculated 
and CFA inoculated groups showed a strong 
proliferation after further IRBP R16 peptide 
stimulation in vitro (Table 1). In comparison, the 
proliferative responses of LNCs to R16 peptide were 
significantly reduced after immunization with Vβ 8.3 
peptide. The inhibition of proliferation was more 
pronounced in the fourfold inoculated group [(17.9±
5.1)% of proliferation] than the twofold group[(30.8± 
Fig. 1. Ocular changes of Lewis rats after immunization with IRBP R16 peptide
emulsified in CFA. A severe inflammation in the anterior chamber is observed in the
noninoculated group (A) and CFA inoculated group (B) as compared with the normal 
group (C), twofold inoculated group (D) and fourfold inoculated group (E). 
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Table 1. Effect of vaccination with Vβ 8.3 peptide on the proliferative responses of lymphocyte proliferation  
assay (mean±SD, cpm of triplicate wells) 
Stimulants Noninoculated group CFA inoculated group Twofold 
inoculated group
Fourfold 
inoculated group 
F value P value 
Medium 3.51±1.73 4.3±1.8 3.6±1.3 3.9±1.7   2.03   0.142 
Vβ 8.3 peptide  3.29±2.56Δ  4.9±2.7Δ 13.8±4.9* 22.5±5.3* 258.91 ＜0.001 
IRBP R16 peptide 33.27±7.24* 31.6±7.5* 10.5±5.2#  6.3±2.1#   3.15   0.048 
*
P＜0.05 compared with the values without stimulant. # P＜0.01 compared with noninoculated group and CFA inoculated group when stimulated with R 16 
peptide. Δ P＜0.01 compared with noninoculated group and CFA inoculated group when stimulated with Vβ 8.3 peptide. 
 
 
 
Fig. 4. Histological grades of the rats 14 days after 
immunization with IRBP R16. Each point is the score of 
an individual animal. The average scores of the group 
are denoted by the horizontal bars. Non-I: noninoculated 
group; CFA-I: CFA inoculated group; Two-I: twofold 
inoculated group; Four-I: fourfold inoculated group. 
 
6.9)%]. To examine immunogenicity of the peptide 
used for vaccination, LNC were exposed again to Vβ 
8.3 peptide in vitro.  The responses of LNC from the 
vaccinated rats to the Vβ 8.3 peptide were 
significantly higher than the noninoculated and CFA 
inoculated rats.  
 
Skewing of Th1/Th2 cytokine balance  
after vaccination 
To examine the possibility that TCR Vβ 8.3 peptide 
 
 
Fig. 5. DTH responses to IRBP R16 at each group. 
Significantly, suppressed DTH responses to IRBP R16 
are noted in the fourfold inoculated group and the 
twofold inoculated group as compared with those in the 
noninoculated group and CFA inoculated group. *P<0.05. 
Non-I: noninoculated group; CFA-I: CFA inoculated 
group; Two-I: twofold inoculated group; Four-I: fourfold 
inoculated group. 
 
vaccination induces an alteration of Th1 dominant 
response that is known to mediate EAU, the cytokine 
concentrations in the aqueous humour and super- 
natants were measured by ELISA. As shown in Fig 
6A, the concentration of IL-2 in aqueous humour of 
the Vβ 8.3 peptide inoculated groups [twofold (212.5
±31.9) pg/ml and fourfold (83.5±12.5) pg/ml] was 
significantly lower than that in the noninoculated 
group [(452.3±67.8) pg/ml] and CFA inoculated group 
Fig. 3. Histological changes of EAU induced by IRBP R16 (haematoxylin eosin staining,
original magnification ×200). The results showing severe retinal destruction, loss of
photoreceptor layer, retinal folding and massive infiltration of inflammatory cells in the retina
and subretinal space of noninoculated rats (A) and CFA inoculated rats (B), a slight
infiltration of inflammatory cells in the retina in the twofold inoculated rats (C) and the
fourfold inoculated rats (D) on day 14 after immunization with IRBP R16. No inflammation is
observed in the normal rats (E).
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Fig. 6. Cytokine concentrations in aqueous humour and supernatants of cultured cells from drained lymph node and spleen. 
Cytokine concentrations were measured in duplicate via ELISA. The results represent the average of each group. Ordinate 
is a log scale. *P< 0.05 compared with noninoculated group and CFA inoculated group. A: IL-2 concentrations in aqueous 
humour; B: cytokine concentrations in the supernatants of cultured cells from draining lymph node; C: cytokine 
concentrations in the supernatant of cultured splenocytes. Non-I: noninoculated group; CFA-I: CFA inoculated group; Two-I: 
twofold inoculated group; Four-I: fourfold inoculated group. 
 
[(440.8± 66.1) pg/ml]. After R16 peptide further 
stimulation in vitro, LNCs and splenocytes from both 
twofold and fourfold inoculated groups produced 
somewhat lower levels of IFN-( and IL-2 and 
significantly higher level of IL-10 than those in the 
noninoculated and CFA inoculated groups (Fig. 6C). 
LNCs from the fourfold inoculated group, but not the 
twofold inoculated group, also secreted significantly 
more IL-4 than those from noninoculated and CFA 
inoculated groups. There was no significant 
difference between the noninoculated and CFA 
inoculated groups concerning cytokine levels in the 
culture super- natants and aqueous humour. 
 
Expression profile of the TCR Vβ 8.3 gene 
Real time quantitative PCR was performed to 
analyze the impact of TCR Vβ 8.3 vaccination on the 
expression of its gene in CD4+ T cells of the spleens.  
The expression of TCR Vβ 8.3 gene on CD4+ T cells 
was indicated by copy numbers (Table 2). A 
significantly higher expression of TCR Vβ 8.3 gene 
was found in the noninoculated, CFA inoculated and 
twofold inoculated groups than that in the normal 
group.  The expression of TCR Vβ 8.3 gene in the 
fourfold inoculated group was close to that in the 
control group and significantly lower than that in the 
noninoculated and CFA inoculated groups. A small 
reduction of Vβ 8.3 gene expression was also 
observed in the twofold inoculated group as 
compared with the CFA inoculated and 
noninoculated groups. The expression of TCR Vβ 8.3 
gene in the noninoculated group and the CFA 
inoculated group was essentially identical.  
Table 2. Expression of TCR Vβ 8.3 gene on splenic  
CD4+ T cells of rats in each group 
Groups Copy numbers 
Noninoculated group (3.39±2.17)×107 
CFA inoculated group (3.06±0.83)×107 
Twofold inoculated group (2.39±0.67)×107 
Fourfold inoculated group (3.31±3.16)×106 
Normal group (7.95±6.43)×105 
F value 59.24 
P value ＜0.001 
 
DISCUSSION 
 
This study showed that EAU was prevented by 
immunization of rats with a synthetic TCR V region 
peptide. The TCR Vβ 8.3 peptide emulsified with the 
strong adjuvant CFA was shown to be immunogenic 
and capable of suppressing the immune response to 
an uveitogenic IRBP peptide in Lewis rats. A high 
inoculation frequency, i.e. 4 injections with intervals 
of 10 days, was more effective than 2 injections with 
an interval of 20 days, in reducing the severity and 
duration of EAU. The adjuvant alone did not show 
any effect in the prevention of EAU. 
 
Since autoreactive CD4+ T cells have been 
considered to be involved in the initiation of 
autoimmune diseases, utilization of a vaccine 
targeting these cells may represent a desirable 
strategy to prevent these diseases. Immunization 
with attenuated autoreactive T cells, known as T cell 
vaccine, has been shown to be effective to prevent 
EAE.12 The study by Beraud et al13 also showed a 
protective effect of T cell vaccination in the course of 
EAU. However, the use of T cell vaccines may be 
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limited because these cells are individually specific 
and should be inoculated with attenuated autologous 
autoreactive T cell clones to reach a protective effect.  
Therefore, recent studies have focused on 
vaccinations that allow a universal prevention of 
autoimmune diseases. TCR peptide vaccination 
seems to be one of the options.14 Studies of T cell 
mediated diseases in animal models have indicated 
that the pathogenic T cells require a limited number 
of TCR gene elements for recognition of 
autoantigens.15 This characteristic of autoreactive T 
cells suggests a possibility for selective immuno- 
therapy. To test this assumption, a number of 
investigators have used synthetic peptide as 
vaccines comprising amino acid sequences from the 
TCR of autoreactive T cells in autoimmune disease 
models.16-21 Immunization with some of these 
peptides showed promise in prevention of diseases, 
induced by autoantigens, such as autoimmune 
arthritis18 and EAE.19-21 However, in some reports, 
the efficacy was variable.22-25 The discrepancy 
between these studies concerning the effects of the 
vaccine might be the result of the use of different 
types of adjuvants. TCR peptide vaccines provide a 
protection against autoimmune diseases only when 
injected with mycobacterium enriched CFA. The 
combination of TCR peptide with mycobacterium 
enriched CFA induces a sufficient number of peptide 
reactive regulatory T cells that mediate specific 
immune inhibition.26  
 
Previous studies on EAU have shown an increased 
expression of TCR Vβ 8.3 gene on CD4+ T cells,9 
which was reproduced in the present study. These 
results suggest that TCR Vβ 8.3-bearing cells may 
play an important role in the development of EAU 
and that a selective deletion or suppression of the Vβ 
8.3-expressing T cell subset could provide an 
effective therapeutic strategy without having to use a 
generalized immunosuppressive regime. Therefore, 
we investigated whether the vaccination of Lewis 
rats with a 21 amino acid sequence of TCR Vβ 8.3 
peptide comprising the core of the immunogenic 
activity,27,28 together with mycobacterium enriched 
CFA as adjuvant, could block the development of 
EAU. Additionally, in an attempt to examine whether 
the adjuvant has influence on EAU, control groups 
included rats injected with CFA and PBS four times 
according to the protocol used in the fourfold 
inoculated group. Our data exclude the possibility 
that CFA alone prevents the induction of EAU. The 
protocols of 2 and 4 inoculations were used to 
examine the effect of TCR Vβ 8.3 vaccination on 
inhibiting the development of EAU. Both protocols 
were effective in prevention against EAU, as judged 
by clinical and histopathological criteria. However, a 
stronger efficacy was consistently found in the 
fourfold inoculated group than in the twofold 
inoculated group, suggesting that the dosage of this 
type of vaccine is important in achieving an ideal 
effect. 
 
DTH and LPA were used to determine the correlation 
between the severity of EAU and antigen specific 
cellular immune responses. The results showed that 
TCR peptide vaccination suppressed the DTH 
response as well as the lymphocyte proliferation to 
the IRBP R16 peptide. In addition, the draining LNCs 
showed a significant proliferation of the Vβ 8.3 
peptide in the inoculated groups. This demonstrated 
that the peptide vaccine was highly immunogenic 
and could induce an intensive cellular immune 
response against the R16-specific T cells, thereby 
inhibiting the development of EAU.26,29 
 
Cytokines are essential components in the 
pathogenesis of EAU. It has been well documented 
that Th1 cytokines exacerbate whereas Th2 
cytokines ameliorate the inflammatory process of 
EAU.30 Therefore, we examined the possibility of 
cytokine shifting induced by vaccination. IFN-( and 
IL-2, predominantly Th1 derived, were decreased in 
production in the vaccinated groups. Th2 derived and 
antiinflammatory cytokines IL-10 and IL-4 were in 
general upregulated after vaccination except for IL-4 
produced by LNCs from the twofold inoculated group. 
The change in the Th1/Th2 cytokine profile paralleled 
the reduction in clinical severity of EAU. In view of 
the fact that inflammation occurs in the intraocular 
tissues, we measured the local concentration of IL-2, 
a Th1 cytokine that has been shown to make an 
important contribution to the development of EAU.31 
The result revealed a significantly decreased IL-2 
concentration in aqueous humour after TCR Vβ 8.3 
peptide immunization. They all suggest that TCR Vβ 
8.3 peptide might induce a switch from Th1 to Th2, 
which results in the inhibition of disease 
progression.32,33 
 
To investigate the changes generated by the peptide 
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vaccine at molecular level, we also detected the 
expression of TCR Vβ 8.3 gene using real time PCR.  
A marked decrease in the expression of Vβ 8.3 gene 
was noted in the rats receiving fourfold inoculation as 
compared with the noninoculated and CFA 
inoculated rats. It is at present unclear whether the 
peptide vaccine directly or indirectly suppresses the 
expression of TCR Vβ 8.3 gene. Further studies are 
needed to address this question.  
 
We found in this study that some of the rats in the 
fourfold inoculated group could not achieve a 
complete prevention against EAU. Possibly TCR Vβ 
8.3 utilization is not exclusive and that other TCR Vβ 
gene segments are involved in the initiation of 
EAU.9,34 Vaccination with TCR Vβ 8.3 peptide alone 
may not be sufficient to control ocular inflammation 
during the course of EAU. Therefore, studies are 
needed to investigate the potential of vaccination 
with other TCR Vβ peptides in the prevention of EAU. 
 
In conclusion, the present study favours the idea that 
sufficient vaccination with TCR Vβ 8.3 peptide 
decreases the expression of TCR Vβ 8.3 gene and 
inhibits the proliferation responses as well as DTH 
reactions specific to IRBP R16 peptide. TCR Vβ 8.3 
peptide also induces a cytokine switch from Th1 to 
Th2 dominance. These mechanisms together lead to 
an effective prevention against EAU induced by 
IRBP R16. The future investigation of the 
predominant usage of TCR Vβ genes in patients 
suffered from autoimmune uveitis is likely to aid in 
designing a new strategy for the prevention and 
treatment of this kind of autoimmune disease. 
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